公开(公告)号：WO2021203190A1

公开(公告)日：2021-10-14

申请号：PCT/CA2021/050452

申请日：2021-04-05

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： FLETCHER, Graham ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: A61K31/5377 ,  A61K39/395 ,  A61P35/00 ,  C07D413/10 ,  C07K16/28

Abstract: Provided herein are methods of treating triple negative breast cancer using an effective amount of Compound (I) represented by the formula: or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor, wherein the checkpoint inhibitor is a PD-1 inhibitor or a PD-L1 inhibitor. Uses of an effective amount of Compound [I] and an effective amount of an immune checkpoint inhibitor, wherein the checkpoint inhibitor is a PD-1inhibitor or a PD-L1 inhibitor for treating triple negative breast cancer are also provided herein.

公开(公告)号：WO2020146946A1

公开(公告)日：2020-07-23

申请号：PCT/CA2020/050042

申请日：2020-01-16

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： BROKX, Richard ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: C07K16/28 ,  A61K39/395 ,  A61P29/00 ,  A61P35/00 ,  A61P35/02 ,  A61P37/02 ,  A61P37/06 ,  C12N15/13 ,  C12P21/08

Abstract: The invention provides novel anti-LILRB3 antibodies, pharmaceutical compositions comprising such antibodies, and therapeutic methods of using such antibodies and pharmaceutical compositions for the treatment of diseases such as cancer, autoimmune disease, or allergic inflammation. This invention can also be used to modulate osteoclast differentiation.

公开(公告)号：WO2019046949A1

公开(公告)日：2019-03-14

申请号：PCT/CA2018/051086

申请日：2018-09-07

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： MASON, Jacqueline M. ,  BRAY, Mark R. ,  MAK, Tak Wah ,  FLETCHER, Graham

IPC: A61K31/5377 ,  A61K39/395 ,  A61P35/00 ,  C07D413/10

Abstract: Provided herein are methods of treating cancer using an effective amount of a compound represented by the formula (Formula (I)) or a pharmaceutically acceptable salt thereof and an effective amount of an immune checkpoint inhibitor. Also provided are compositions comprising the same compound represented by the formula shown above or a pharmaceutically acceptable salt thereof and an immune checkpoint inhibitor.

公开(公告)号：EP4452266A1

公开(公告)日：2024-10-30

申请号：EP22908968.5

申请日：2022-12-21

Applicant: University Health Network

Inventor： BRAY, Mark R. ,  MASON, Jacqueline M. ,  WEI, Xin ,  DUNCAN, Gordon

IPC: A61K31/437 ,  A61P35/02 ,  C07D471/04

公开(公告)号：EP3678669A1

公开(公告)日：2020-07-15

申请号：EP18854876.2

申请日：2018-09-07

Applicant: University Health Network

Inventor： MASON, Jacqueline M. ,  BRAY, Mark R. ,  MAK, Tak Wah ,  FLETCHER, Graham

IPC: A61K31/5377 ,  A61K39/395 ,  A61P35/00 ,  C07D413/10

公开(公告)号：EP3212652A1

公开(公告)日：2017-09-06

申请号：EP15855932.8

申请日：2015-10-09

Applicant: University Health Network

Inventor： LAUFER, Radoslaw ,  NG, Grace ,  BROKX, Richard ,  PAULS, Heinz W. ,  LI, Sze-wan ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: C07D487/04 ,  A61K31/519 ,  A61P29/00 ,  A61P35/00 ,  A61P37/06

CPC classification number: A61K31/519 ,  A61K45/06 ,  C07D487/04

Abstract: The invention is a compound represented by Structural Formula (I): (I); or a pharmaceutically acceptable salt thereof. Values for the variables are provided herein. Also included is a pharmaceutical composition comprising the compound represented by Structural Formula (I) and a pharmaceutically acceptable carrier or diluent and methods of treating a subject with cancer with the compound of Structural Formula (I).

Abstract translation: 本发明是由结构式（I）表示的化合物：（I）; 或其药学上可接受的盐。 这里提供了变量的值。 还包括包含由结构式（I）表示的化合物和药学上可接受的载体或稀释剂的药物组合物以及用结构式（I）的化合物治疗患有癌症的个体的方法。

公开(公告)号：EP4069246A1

公开(公告)日：2022-10-12

申请号：EP20895810.8

申请日：2020-12-04

Applicant: University Health Network

Inventor： BRAY, Mark R. ,  MASON, Jacqueline M. ,  FLETCHER, Graham

IPC: A61K31/5377 ,  A61K31/194 ,  A61P35/02 ,  C07C57/15 ,  C07D413/14

公开(公告)号：EP2588110B1

公开(公告)日：2018-10-17

申请号：EP11800027.2

申请日：2011-07-04

Applicant: University Health Network

Inventor： PAN, Guohua ,  MASON, Jacqueline M. ,  WEI, Xin ,  FEHER, Miklos

IPC: A61K31/496 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/4439 ,  A61P35/00

CPC classification number: A61K31/416 ,  A61K31/4439 ,  A61K31/495 ,  A61K31/496 ,  A61K31/497 ,  A61K31/5377

Abstract: Provided herein are methods, uses and compositions for treating a patient with cancer wherein the cancer is characterized by a PTEN gene mutation. In particular embodiments, the methods comprise administering to the patient a composition comprising a therapeutically effective amount of a PLK4 antagonist, and identifying a patient that is likely to be responsive to PLK4 antagonist therapy, if PTEN gene mutation is present.

公开(公告)号：EP4305068A1

公开(公告)日：2024-01-17

申请号：EP22766049.5

申请日：2022-03-11

Applicant: University Health Network

Inventor： BROKX, Richard ,  MASON, Jacqueline M. ,  BRAY, Mark Robert ,  DUNCAN, Gordon S.

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61P37/02 ,  A61P37/06 ,  C12N15/13 ,  C12P21/08

公开(公告)号：EP3938389A1

公开(公告)日：2022-01-19

申请号：EP20769649.3

申请日：2020-03-11

Applicant: University Health Network

Inventor： BROKX, Richard ,  MASON, Jacqueline M. ,  BRAY, Mark R.

IPC: C07K16/18 ,  A61K39/395 ,  C12N15/13 ,  C12P21/08